EA201070053A1 - Композиции и способы, ингибирующие грипп - Google Patents

Композиции и способы, ингибирующие грипп

Info

Publication number
EA201070053A1
EA201070053A1 EA201070053A EA201070053A EA201070053A1 EA 201070053 A1 EA201070053 A1 EA 201070053A1 EA 201070053 A EA201070053 A EA 201070053A EA 201070053 A EA201070053 A EA 201070053A EA 201070053 A1 EA201070053 A1 EA 201070053A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
influenza virus
peptide
fir
compositions
Prior art date
Application number
EA201070053A
Other languages
English (en)
Other versions
EA017957B1 (ru
Inventor
Роберт Ф. Гарри
Рассел Б. Уилсон
Original Assignee
Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд
АУТОИММЬЮН ТЕКНОЛОДЖИЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд, АУТОИММЬЮН ТЕКНОЛОДЖИЗ, ЭлЭлСи filed Critical Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд
Publication of EA201070053A1 publication Critical patent/EA201070053A1/ru
Publication of EA017957B1 publication Critical patent/EA017957B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к пептидам, аналогам пептидов, производным пептидов и к фармацевтическим композициям, пригодным для лечения или профилактики инфекции вирусом гриппа или профилактики передачи от лица к лицу инфекции вирусом гриппа. Пептид по изобретению содержит часть, ингибирующую слияние вирус гриппа-клетка, области инициации слияния (FIR) белка гемагглютинина 2 вируса гриппа дикого типа или ее вариант. В предпочтительном варианте изобретения пептид по изобретению состоит из от 8 до 40 последовательно расположенных аминокислотных остатков части белка гемагглютинина 2 вируса гриппа дикого типа или его варианта, причем часть белка содержит FIR белка и вплоть до пяти аминокислотных остатков на аминоконцевой и карбоксиконцевой сторонах FIR.
EA201070053A 2007-06-25 2008-06-25 Композиции и способы, ингибирующие грипп EA017957B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93712007P 2007-06-25 2007-06-25
PCT/US2008/007918 WO2009002516A1 (en) 2007-06-25 2008-06-25 Influenza inhibiting compositions and methods

Publications (2)

Publication Number Publication Date
EA201070053A1 true EA201070053A1 (ru) 2010-08-30
EA017957B1 EA017957B1 (ru) 2013-04-30

Family

ID=40185954

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070053A EA017957B1 (ru) 2007-06-25 2008-06-25 Композиции и способы, ингибирующие грипп

Country Status (18)

Country Link
US (2) US8604165B2 (ru)
EP (1) EP2170365B1 (ru)
JP (2) JP5450402B2 (ru)
KR (4) KR101660363B1 (ru)
CN (2) CN105237629B (ru)
BR (1) BRPI0813922A2 (ru)
CA (1) CA2691358C (ru)
DK (1) DK2170365T3 (ru)
EA (1) EA017957B1 (ru)
ES (1) ES2581381T3 (ru)
HK (2) HK1142804A1 (ru)
HU (1) HUE029921T2 (ru)
IL (2) IL202450A (ru)
MX (2) MX2009013635A (ru)
PL (1) PL2170365T3 (ru)
PT (1) PT2170365T (ru)
WO (1) WO2009002516A1 (ru)
ZA (1) ZA200909130B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110126501A1 (en) 2009-10-16 2011-06-02 Woongjin Coway Co., Ltd. Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter
KR101153630B1 (ko) * 2009-10-16 2012-06-18 웅진코웨이주식회사 타닌산을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
EP3492101A3 (en) * 2012-05-10 2019-10-23 Massachusetts Institute Of Technology Agents for influenza neutralization
US9649375B2 (en) * 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
EP3548056A4 (en) * 2016-12-02 2020-08-12 Emory University PEPTIDES AND USES FOR VIRUS INFECTION MANAGEMENT
IL298035A (en) 2020-05-08 2023-01-01 Academia Sinica Chimeric influenza vaccines
CN113801206A (zh) * 2020-06-15 2021-12-17 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
WO2021253172A1 (zh) * 2020-06-15 2021-12-23 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1711888A (en) 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5567805A (en) * 1990-03-09 1996-10-22 Administrators Of The Tulane Educational Fund The cellular receptor for the CS3 peptide of human immunodeficiency virus
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6310180B1 (en) * 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
US6037348A (en) * 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
AU732916C (en) * 1996-11-14 2002-06-06 Biota Scientific Management Pty Ltd Method and novel compounds for use therein
GB9712892D0 (en) * 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
CA2398787A1 (en) 2000-02-10 2001-08-16 Panacos Pharmaceuticals, Inc. Assay for detection of viral fusion inhibitors
GB0022969D0 (en) * 2000-09-19 2000-11-01 Chiron Spa Influenza a virus subtype H16
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7894999B2 (en) * 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
EP1603590A4 (en) * 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
WO2005016238A2 (en) 2003-05-08 2005-02-24 Duke University Severe acute respiratory syndrome
TW200510450A (en) 2003-07-21 2005-03-16 Nat Inst Health Soluble fragments of the SARS-CoV spike glycoprotein
PT2261376E (pt) * 2003-11-04 2013-09-23 Univ Tulane Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe i
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
DE102005060920A1 (de) * 2005-12-18 2007-06-21 Charité - Universitätsmedizin Berlin Peptide für die Wechselwirkung mit alpha-helikalen Coiled-Coil-Strukturen und/oder Coiled-Coil-Sequenzen, davon abgeleitete Mittel und ihre Verwendung
AU2007300663A1 (en) * 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions

Also Published As

Publication number Publication date
IL238404A0 (en) 2015-06-30
JP5764621B2 (ja) 2015-08-19
MX363240B (es) 2019-03-15
ZA200909130B (en) 2010-09-29
AU2008269081A1 (en) 2008-12-31
HUE029921T2 (en) 2017-04-28
US9353157B2 (en) 2016-05-31
PT2170365T (pt) 2016-07-12
EP2170365A1 (en) 2010-04-07
DK2170365T3 (en) 2016-09-05
CN105237629A (zh) 2016-01-13
KR20160113331A (ko) 2016-09-28
US20100152109A1 (en) 2010-06-17
CA2691358C (en) 2017-08-22
CN101848719A (zh) 2010-09-29
MX2009013635A (es) 2010-05-19
KR20100056442A (ko) 2010-05-27
KR101660363B1 (ko) 2016-09-28
US20140194347A1 (en) 2014-07-10
KR101719135B1 (ko) 2017-03-23
JP5450402B2 (ja) 2014-03-26
BRPI0813922A2 (pt) 2017-05-09
ES2581381T3 (es) 2016-09-05
IL202450A0 (en) 2011-08-01
JP2010531362A (ja) 2010-09-24
PL2170365T3 (pl) 2017-03-31
WO2009002516A1 (en) 2008-12-31
EP2170365B1 (en) 2016-05-25
EP2170365A4 (en) 2012-05-02
KR20180021930A (ko) 2018-03-05
IL238404A (en) 2017-03-30
IL202450A (en) 2015-05-31
US8604165B2 (en) 2013-12-10
HK1215037A1 (zh) 2016-08-12
HK1142804A1 (zh) 2010-12-17
CN105237629B (zh) 2019-06-18
CA2691358A1 (en) 2008-12-31
EA017957B1 (ru) 2013-04-30
KR20150117303A (ko) 2015-10-19
CN101848719B (zh) 2015-09-23
JP2013241432A (ja) 2013-12-05

Similar Documents

Publication Publication Date Title
EA201070053A1 (ru) Композиции и способы, ингибирующие грипп
ATE549028T1 (de) Stabile analoga von glp-1
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
WO2002008251A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2005292135B2 (en) Inhibitors of hepatitits C virus
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
WO2010068761A3 (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
US11304989B2 (en) Peptides for use in the treatment of viral infections
ATE469657T1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
MX2023000041A (es) Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.
RU2005123050A (ru) Супер-антигенные фьюжн-белки и их использование
WO2005002500A3 (en) Inhibitors of coronavirus
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
JP2019506840A5 (ru)
MX2018002616A (es) Proteina de fusion.
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
WO2012162637A3 (en) Vaccine adjuvants from self-assembling peptides
WO2005075679A3 (en) Antigenic hiv-1 peptides
HRP20140819T1 (hr) MUTIRANI TAT OYI PROTEIN ZA PREVENCIJU ILI LIJEÄŚENJE AIDS-a
KR20190071714A (ko) 인플루엔자 바이러스 중화 화합물
WO2020144355A3 (fr) Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre
WO2006088664A3 (en) Flavivirus ns5a proteins for the treatment of hiv

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU